Viridian Therapeutics, Inc.\DE (VRDN) EBITDA Margin (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly EBITDA Margin of 82389.36% for Q1 2026, up 4798008.0% year-over-year from N/an in Q1 2025, and up 11.4% quarter-over-quarter from 92991.67% in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) EBITDA Margin (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's EBITDA Margin history runs 14 years deep, the most recent figure standing at 82389.36% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 4798008.0% year-over-year to 82389.36%; the TTM figure through Mar 2026 stood at 543.86% (up 11104719.0% YoY), while the FY2025 annual figure was 512.91%, up 9850530.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 82389.36%, up from 92991.67% in the prior quarter.
- The five-year high for EBITDA Margin was 56.7% in Q3 2025, with the low at 142356.0% in Q2 2025.
- The 5-year median for EBITDA Margin is 82326.39% (2023), against an average of 73180.6%.
- The sharpest annual moves came in 2023 and 2025: EBITDA Margin plunged 7077795 bps in 2023, then soared 9701307 bps in 2025.
- Viridian Therapeutics, Inc.\DE's EBITDA Margin stood at 46729.52% in 2022, then slumped by 112 bps to 99275.0% in 2023, then decreased by 22 bps to 121488.89% in 2024, then gained by 23 bps to 92991.67% in 2025, then gained by 11 bps to 82389.36% in 2026.
- Business Quant data shows VRDN's EBITDA Margin at 82389.36% in Q1 2026, 92991.67% in Q4 2025, and 56.7% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | -44,460.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44,460.56% |
| Mar 31, 2026 | -82,389.36% |
| Dec 31, 2025 | -92,991.67% |
| Sep 30, 2025 | -56.70% |
| Jun 30, 2025 | -142,356.00% |
| Mar 31, 2025 | -130,369.44% |
| Dec 31, 2024 | -121,488.89% |
| Sep 30, 2024 | -97,069.77% |
| Jun 30, 2024 | -100,259.72% |
| Mar 31, 2024 | -77,634.72% |
| Dec 31, 2023 | -99,275.00% |
| Sep 30, 2023 | -71,144.44% |
| Jun 30, 2023 | -82,326.39% |
| Mar 31, 2023 | -73,952.04% |
| Dec 31, 2022 | -46,729.52% |
| Sep 30, 2022 | -2,492.47% |
| Jun 30, 2022 | -11,548.44% |
| Mar 31, 2022 | -11,985.65% |
| Dec 31, 2021 | -13,589.25% |
| Sep 30, 2021 | -6,795.19% |